Figure 2 | Scientific Reports

Figure 2

From: Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options

Figure 2

Continued use of trastuzumab in HER2+ breast cancer with PTEN inactivation induces subtype switching from HER2+ to a triple negative like breast cancer.

(A) Normalized mRNA expression (reads/kilobase/million reads) of breast cancer subtype markers ER, PR, HER2 and Ki-67 determined by RNA sequencing in Parental BT474 and BT474 PTEN− LTT cell lines N = 4.(B) Western blot representing breast cancer subtype markers ER, PR, HER2 and PTEN with β-actin as loading control. (C) Immunohistological staining of breast cancer subtype markers in primary BT474 and BT474 PTEN− LTT xenografts when tumors reached 500 mm3. (D) mRNA expression of HER2 signal transducer AKT1 as determined by RNA sequencing. (E) Normalized protein expression of AKT1 in cell lines by ELISA assay. N = 3. Data shown as average ± SD. #p ≤ 0.01.

Back to article page